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TO THE EDITOR
Lentigo maligna melanoma (LM, i.e.,
in situ melanoma) together with its
invasive form lentigo maligna mela-
noma (LMM) is a subtype of malignant
melanoma with specific and distinct
characteristics compared with the other
subtypes of malignant melanoma (super-
ficial spreading melanoma, nodular
melanoma, and acral lentiginous mela-
noma). In contrast to other subtypes,
LM predominantly occurs on chronically
sun-damaged skin of elderly people
and is the most frequent malignant
melanoma found in the face (Cohen,
1995). Another characteristic feature of
LM is the location of atypical melano-
cytes along the dermal–epidermal junc-
tion, where they are arranged in solitary
units or small nests. Because of these
features, the proportion of tumor cells
within the lesion is usually rather small,
rendering molecular characterization
challenging.
Mutations in the BRAF gene have
been shown to be a common, early
event in melanoma development
(Ko and Fisherm, 2011) and because of
recent advances in the treatment of
metastatic melanoma, the mutational
status of BRAF has become therapy
decisive (Sosman et al., 2012). So far,
only little information is available
on the BRAF V600E and BRAF V600K
mutations in LM. Therefore, the objec-
tive of this study was to determine the
occurrence of mutations in codon 600
of the BRAF gene in a large cohort of
LM patient samples using a highly
sensitive PCR method (Stadelmeyer,
2012).
We analyzed tissue samples from
61 patients (36 women and 25 men;
median age, 73.9 years; age ranging
from 43.5 to 94.5 years). A total of 59
patients had LM and two patients had a
lesion with invasive tumor cells (i.e.,
LMM). LM-adjacent (normal) skin was
available from 39 samples, and DNA
was extracted and analyzed for the
presence of BRAF mutations as descri-
bed in the Supplementary Information.Accepted article preview online 9 August 2013; published online 12 September 2013
Abbreviation: BRAF, v-raf murine sarcoma viral oncogene homolog B1
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Using AS PCR, the BRAF V600K muta-
tion was exclusively found in the DNA
from the tumor area in 10/61 (16%)
samples, whereas the BRAF V600E
mutation was found in 3/61 (5%) DNA
samples from the tumor area and in 2/39
(5%) DNA samples from tumor-adjacent
skin (Figure 1). These two samples
revealed no BRAF V600 mutations in
the tumor area. Thus, the incidence of
the BRAF V600K mutation was signifi-
cantly higher in the DNA from the tumor
area compared with the DNA from the
surrounding area (P¼0.006). Details on
samples and mutational status are given
in Supplementary Table S1 online.
We found that BRAF mutations were
present in 13/61 (21%) of the melanoma
lesions and that the BRAF V600K muta-
tion predominated over the BRAF
V600E mutation (10/61 (16%) and 3/61
(5%), respectively). This finding is in line
with the observation by Menzies et al.
(2012) who showed a correlation bet-
ween the BRAF V600K mutation and
melanomas on skin with chronic sun-
induced damage. All mutations detected
in the DNA from tumor, as well as in the
DNA from adjacent normal skin tissue,
were low-level mutations, meaning that
the mutations were found in the DNA
sample to an extent of o5% of mutated
DNA in a background of wild-type
DNA. Detection of low-level mutations
requires methods with adequate sensi-
tivity. The current gold-standard of
specificity in mutation analysis, Sanger
sequencing, shows a lower limit of
detection in a range between 5 and
20% of mutated DNA in a background
of wild-type DNA (Miller et al., 2004;
Spittle et al., 2007). Thus, mutation
analysis using Sanger sequencing may
miss low-level mutations because of its
moderate sensitivity. This may lead to
discrepancies in mutation frequencies
found in tumor DNA when compared
with results using methods with higher
sensitivity like AS PCR (Pollock et al.,
2003; Miller et al., 2004; Lassacher
et al., 2006). Comparing our results
with data from the literature (Table 1),
we found that the strengths of our study
are its sample size and the high sensi-
tivity of the method used for mutation
Table 1. Prevalence of BRAF V600 mutations in LM samples in previous studies1
BRAF mutation status of LMM
Reference
No. of all
types of melanomas
No. of
LM(M)
Wild
type V600E V600K
Not E
or K
Mutated
portion (%) Detection method
Akslen et al., 2008 97 20 17/20 1/20 2/20 3/20 (15) Sequencing2
Deichmann et al., 2004 50 1 1/1 1/1 (100) SSCP, sequencing
Hacker et al., 2010, 2013 3 123 34 30/34 4/34 (12) iPLEX genotyping4
Lang and MacKie, 2005 52 10 8/10 2/10 2/10 (20) dHPLC, AS PCR, sequencing
Maldonado et al., 2003 3 115 9 8/9 1/9 (11) Sequencing
Menzies et al., 2012 308 4 4/4 0/4 (0) High-resolution melting analysis
Omholt et al., 2003 3 69 1 1/1 (100) Sequencing, SSCP
Poynter et al., 2006 3 80 20 19/20 1/20 (5) Sequencing
Saldanha et al., 2006 3 59 13 6/13 7/13 (54) RFLP, SSCP
Sasaki et al., 2004 35 5 5/5 Sequencing, ASO hybridization
Ugurel et al., 2007 97 2 2/2 Sequencing
Viros et al., 2008 3 302 39 26/39 13/39 (33) Sequencing
Abbreviations: LM, lentigo maligna melanoma; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism.
1This—by no means exhaustive table—shows selected publications, only.
2Sequencing denotes methods on the basis of Sanger sequencing but does not differentiate direct sequencing from cycle sequencing.
3Published data do not allow differentiation between BRAF V600 mutations.
4Authors indicated a sensitivity of the iPLEX assay to detect 1.5–3% mutated alleles in the sample.
Tumor (n=61) Adjacent non-
tumor (n=39)
Wt
BRAF V600E
BRAF V600k
n=10; 16%**
n=3; 5%
n=2; 5%
n=48; 79% n=37; 95%
Figure 1. Frequencies of BRAF V600E and BRAF V600K mutations in DNA from lentigo maligna
melanoma lesions. (a) Among the 61 DNA samples from the tumor area, the BRAF V600 mutation was
detectable in 13/61 cases (21%): 10 samples carried the BRAF V600K mutation and 3 carried the BRAF
V600E mutation. (b) In 2/39 DNA samples from the tumor-adjacent area, the BRAF V600E mutation was
found. The occurrence of the BRAF V600K mutation was significantly higher in DNA from tumor area
compared with DNA from surrounding area (**P¼0.006). Numbers before the semicolon indicate the
number of samples, and after the semicolon indicate percentages. Wt, wild type.
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analysis. In addition, 39 DNA samples
from tumor-adjacent skin were ana-
lyzed. Although none of the samples
from tumor-surrounding tissue carried a
BRAF V600K mutation, the BRAF V600E
mutation was detected in 2/39 samples.
However, it needs to be noted that in
one of those two cases, a melanocytic
nevus was histopathologically diag-
nosed in the tumor-adjacent skin, a
condition commonly associated with
BRAF V600E mutation (Pollock et al.,
2003; Ichii-Nakato et al., 2006; Poynter
et al., 2006). In general, only few data
are available on BRAF mutations
occurring in tumor-adjacent skin. One
study comparing the mutational status
between tumor and tumor surrounding
tissue was published by Deichmann et al.
(2004). Their results are in line with our
data, as they detected BRAF mutations
predominantly in neoplastic tissue,
except in one case where a mutation
has been found in the corresponding
normal tissue, as they supposed because
of occult tumor cells in this area.
Our results demonstrate the presence
of BRAF V600 mutations in LM and
LMM, with the majority of mutations
being low-level BRAF V600K mutations.
The BRAF V600K mutation was exclu-
sively found in DNA from tumor area
and not in DNA from surrounding
area. One can speculate whether the
different types of mutation (V600K and
not V600E) found in LM result from a
divergent progression of the lesion.
It is noteworthy that Akslen et al.
(2008) found 15% of their LMM sam-
ples to carry a BRAF mutation, whereas
none of the detected mutation was a
BRAF V600E mutation, but a V600K,
L597L, and an E586K mutation. There
seems to be a correlation between the
slow progression of LMM, its preferen-
tial occurrence on chronic sun-damaged
skin in elderly persons, and the
increased presence of the BRAF V600K
mutation (Menzies et al., 2012).
Taken together, the overall mutation
frequency found in the DNA samples
from LM tumor tissue was relatively low
in this study. Only 13/61 (21%) samples
carried V600 mutations in the BRAF
gene, indicating that BRAF mutation
has a role at maximum in a subset of
LM lesions. At this time point, because
of limited long-term follow-up of
the patients enrolled, no conclusion
can be drawn on whether there is
any correlation between the presence
of a BRAF mutation in a LM in situ and
on the probability of tumor progression.
This study has been approved by the
ethical committee of the Medical
University of Graz (24-229 ex 11/12)
and was conducted according to the
Declaration of Helsinki protocols.
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